Objectives: To develop evidence-based guideline recommendations through a systematic
review of the literature to establish standard molecular biomarker testing of colorectal cancer …

Immune checkpoint inhibitors have demonstrated unprecedented clinical activity in a wide
range of cancers. Significant therapeutic responses have recently been observed in patients …

Colorectal Cancer (CRC) is the third most prevalent cancer in men and women. Up to 15%
of CRCs display microsatellite instability (MSI). MSI is reflective of a deficient mismatch …

BACKGROUND: Inherited mutations in deoxyribonucleic acid (DNA) mismatch repair (MMR)
genes lead to an increased risk of colorectal cancer (CRC), gynaecological cancers and …

Microsatellite instability (MSI) is a tumor phenotype linked to somatic or germline (Lynch
syndrome) inactivating alterations of DNA mismatch repair genes. A broad spectrum of …

Background Patients treated with chemotherapy for microsatellite unstable (MSI) and/or
mismatch repair deficient (dMMR) cancer metastatic colorectal cancer (mCRC) exhibit poor …

Cancers acquire multiple somatic mutations that can lead to the generation of immunogenic
mutation-induced neoantigens. These neoantigens can be recognized by the host's immune …

To determine the correlation between BRAF genotype and MLH1 promoter methylation in a
screening program for Lynch syndrome (LS), a universal screening program for LS was …

While the treatment of colorectal cancer continues to rely heavily on conventional cytotoxic
therapy, an increasing number of targeted agents are under development. Many of these …

Background and scope In the epoch of precision medicine and personalised oncology,
which aims to deliver the right treatment to the right patient, molecular genetic biomarkers …